Ascribe Bioscience Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-15.
Ascribe Bioscience Inc. filed a Form D notice of an exempt securities offering with the SEC on October 15, 2025. The filing reports $15.02M sold. Its industry group is Agriculture. It names Jay Farmer (Executive Officer, Director), Frank Schroeder (Director), Kyle Welborn (Director) (SEC Form D, October 15, 2025).
Is this your company?
Sell to companies like Ascribe Bioscience Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ascribe Bioscience Inc.
Free to see. No signup.
More on the people and the money behind Ascribe Bioscience Inc., from the filings we hold.
Agriculture raises filed within 90 days of this one, largest first.
Get an email when Ascribe Bioscience Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ascribe Bioscience Inc. raises, hires or launches. No email unless you switch it on.
Watch Ascribe Bioscience Inc. →Get the full cited report on Ascribe Bioscience Inc.
What the filing shows about Ascribe Bioscience Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ascribe Bioscience Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Ascribe Bioscience Inc.'s address as 95 Brown Road, Suite 202, Ithaca, NY 14850.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Ascribe Bioscience Inc. See pricing
Ascribe Bioscience Inc. is a registered filer with the SEC (CIK 1882999) and has filed since 2024-10-07. 2 filings are on record, the latest on 2025-10-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Ascribe Bioscience Inc.'s Form D of 2025-10-15 names Jay Farmer, Frank Schroeder, Kyle Welborn and 2 more as its officers, directors or promoters.
Its new offerings report $17.17M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 109 filings in Agriculture, totalled by week.
Jay Farmer is named as Executive Officer and Director on the Form D that Ascribe Bioscience Inc. filed with the SEC on 15 October 2025, one of 5 people that filing names.
Frank Schroeder is named as Director on the Form D that Ascribe Bioscience Inc. filed with the SEC on 15 October 2025, one of 5 people that filing names.
Kyle Welborn is named as Director on the Form D that Ascribe Bioscience Inc. filed with the SEC on 15 October 2025, one of 5 people that filing names.
Alex Bondar is named as Director on the Form D that Ascribe Bioscience Inc. filed with the SEC on 15 October 2025, one of 5 people that filing names.
Fred Gruis is named as Director on the Form D that Ascribe Bioscience Inc. filed with the SEC on 15 October 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-10-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Ascribe Bioscience Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ascribe Bioscience Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ascribe Bioscience Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ascribe Bioscience Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Ascribe Bioscience Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Ascribe Bioscience Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/ascribe-bioscience-inc-form-d-25000001